Xintela ABFRA:1XT +6.25%8 Pretax Margin % is -2,668.29% as of Mar. 2026. GuruFocus rates FRA:1XT with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 941 Biotechnology companies, Xintela AB ranks worse than 83.85% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Xintela AB's Pre-Tax Income for the
three
months ended in Mar. 2026 was €-1.09 Mil. Xintela AB's Revenue for the
three
months ended in Mar. 2026 was €0.04 Mil. Therefore, Xintela AB's pretax margin for the quarter that ended in Mar. 2026 was -2,668.29%.
The historical rank and industry rank for Xintela AB's Pretax Margin % or its related term are showing as below:
FRA:1XT'
s Pretax Margin % Range Over the Past 10 Years
Min: -1097250 Med: -74829.49 Max: -985.39
Current: -1983.64
FRA:1XT's Pretax Margin % is ranked worse than 83.85% of 941
companies
in the Biotechnology industry
Industry Median: -90.37
vs FRA:1XT: -1983.64
Xintela AB (FRA:1XT) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Xintela AB Pretax Margin % Related Terms
Xintela AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Xintela AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1XT vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Xintela AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xintela AB Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xintela AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Xintela AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xintela AB (FRA:1XT) has a Pretax Margin % of -2,668.29% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Xintela AB and its competitors. According to the industry distribution chart, Xintela AB ranks #789 out of 941 companies in the Biotechnology industry, placing it in the top 83.8%.
Is Xintela AB's Pretax Margin % too high?
Xintela AB's current Pretax Margin % is -2,668.29%. Based on the distribution chart, Xintela AB ranks #789 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xintela AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Xintela AB's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xintela AB ranks #789 out of 941 companies for Pretax Margin %. This places Xintela AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Xintela AB and its competitors. Xintela AB's current Pretax Margin % is -2,668.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xintela AB stock overvalued right now?
Xintela AB (FRA:1XT) has a current Pretax Margin % of -2,668.29%. The current Pretax Margin % is -2,668.29%. Xintela AB's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Xintela AB (FRA:1XT), the current Pretax Margin % is -2,668.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score
Get the complete analysis for FRA:1XT
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1XT has been successfully added to your 
